Scientists at the University of York are developing a nasal spray that can be used to treat patients with Parkinson's disease. According to Medical Express, the new gel can adhere to tissues inside the nose, along with the included drug Levodopa, helping to deliver therapeutic agents directly to the brain.
In the brain, Levodopa is converted into dopamine, which compensates for the deficiency of dopamine-producing cells in patients with Parkinson's disease. This allows you to cope with the symptoms of the disease. However, over time, the effectiveness of Levodopa decreases, and patients require higher doses.
The problem is that the body begins to break down the drug before it reaches the brain. To solve this problem, researchers have developed a spray with Levodopa. Once in the nasal cavity, the liquid form of the drug turns into a gel.
The new drug delivery method has been tested in animal models. The gel provided better adhesion of the drug inside the nose, which guaranteed its entry into the brain.